Cargando…
Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288743/ http://dx.doi.org/10.1186/2051-1426-2-S3-P78 |
| _version_ | 1782352017498308608 |
|---|---|
| author | Patel, Sapna Milhem, Mohammed Hallmeyer, Sigrun Daniels, Gregory Cranmer, Lee Taback, Bret Flaherty, Lawrence Aung, Sandra Lowder, James Sharfman, William |
| author_facet | Patel, Sapna Milhem, Mohammed Hallmeyer, Sigrun Daniels, Gregory Cranmer, Lee Taback, Bret Flaherty, Lawrence Aung, Sandra Lowder, James Sharfman, William |
| author_sort | Patel, Sapna |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288743 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887432015-01-15 Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02) Patel, Sapna Milhem, Mohammed Hallmeyer, Sigrun Daniels, Gregory Cranmer, Lee Taback, Bret Flaherty, Lawrence Aung, Sandra Lowder, James Sharfman, William J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288743/ http://dx.doi.org/10.1186/2051-1426-2-S3-P78 Text en Copyright © 2014 Patel et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Patel, Sapna Milhem, Mohammed Hallmeyer, Sigrun Daniels, Gregory Cranmer, Lee Taback, Bret Flaherty, Lawrence Aung, Sandra Lowder, James Sharfman, William Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02) |
| title | Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02) |
| title_full | Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02) |
| title_fullStr | Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02) |
| title_full_unstemmed | Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02) |
| title_short | Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02) |
| title_sort | open-label, randomized, multi-center study comparing the sequence of high dose aldesleukin (proleukin(® )(hd il-2) and ipilimumab yervoy(® )) in patients with metastatic melanoma (proclivity 02) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288743/ http://dx.doi.org/10.1186/2051-1426-2-S3-P78 |
| work_keys_str_mv | AT patelsapna openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT milhemmohammed openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT hallmeyersigrun openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT danielsgregory openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT cranmerlee openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT tabackbret openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT flahertylawrence openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT aungsandra openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT lowderjames openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 AT sharfmanwilliam openlabelrandomizedmulticenterstudycomparingthesequenceofhighdosealdesleukinproleukinhdil2andipilimumabyervoyinpatientswithmetastaticmelanomaproclivity02 |